IMRT-SIB and Capecitabine in Preoperative Rectal Cancer Treatment

  • STATUS
    Recruiting
  • participants needed
    50
  • sponsor
    Institute of Oncology Ljubljana
Send
Updated on 8 November 2020
See if I qualify
platelet count
renal function
cancer
capecitabine
primary tumor
rectal carcinoma
adenocarcinoma
adenocarcinoma of rectum

Summary

RATIONALE: Using small radiation beamlets of different intensity, IMRT (intensity modulated radiation therapy) allows shaping the dose around planning target volume with better sparing of normal tissue comparing to 3D conformal radiotherapy. It allows daily delivery of higher dose to the tumor with simultaneous integrated boost (SIB), consequently shortening total treatment time with potentially better response to treatment. In advanced rectal adenocarcinoma excellent response to preoperative radiochemotherapy with complete eradication of the primary tumor observed in the histopathological specimen (pathological complete response, pCR) correlates with a favorable overall prognosis, so trying to achieve better response to preoperative treatment with higher pCR seams feasible.

PURPOSE:The hypothesis of this study is that in preoperative radiochemotherapy for locally advanced rectal adenocarcinoma shortening of the total treatment time with IMRT-SIB to 22 daily fractions concomitant with capecitabine results in an improved pCR rate from 9% (Slovenian trial) to 25%. Secondary objectives are to evaluate pathological down-staging rate, histopathological R0 resection rate, sphincter preservation rate, perioperative surgical complication rate, local control, disease-free survival (DFS), overall survival (OS), late toxicity and quality of life.

Details
Condition Rectal Cancer
Treatment Capecitabine, Surgery, IMRT-SIB
Clinical Study IdentifierNCT02268006
SponsorInstitute of Oncology Ljubljana
Last Modified on8 November 2020

Eligibility

 Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 90 yrs?
Gender: Male or Female
Do you have Rectal Cancer?
Biopsy-proven newly diagnosed primary rectal adenocarcinoma
Locally advanced tumor fulfilling at least one of the following criteria on pelvic
MRI
T 3 or
N 1
Positive mesorectal fascia (MRF), i.e. tumor or lymph node one mm or less from the mesorectal fascia
Tumor located od 0 - 15 cm above anocutaneous junction or below peritoneum
Age 18 years and more
Signed informed consent
WHO Performance Status 0-2
Patients is considered to be mentally and physically ft for chemotherapy as judged by oncologist
Adequate hematological, hepatic and renal function (WBC 3.0 x 109/L, neu 1.5 x 109/L, platelet count 100 x 109/L, renal clearance 50 ml/min, bilirubin 3x normal value, aspartate transaminase/alanine transaminase (AST/ALT) 2,5x normal value)

Exclusion Criteria

T4 inoperable tumor - extensive growth into cranial part of the sacrum (above S3) or the lumbosacral nerve roots
Metastatic or recurrent rectal cancer
Other co-existing malignancy or malignancy within the past 5 years, with the exception of adequately treated in situ carcinoma of the cervix or basal cell carcinoma of the skin
Chronic bowel inflammatory disease
Pregnant or lactating patient
Significant heart disease (uncontrolled hypertension despite of medication (> 150/100 mmHg), New York Heart Association (NYHA) class III or IV heart disease,unstable angina or myocardial infarction within the past 1 year prior the study entry, history of significant ventricular arrhythmia requiring treatment)
Inability to consciously sign the consent form due to physical or psychological disabilities
Clear my responses
Read more

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

platelet count
renal function
cancer
capecitabine
primary tumor
rectal carcinoma
adenocarcinoma
adenocarcinoma of rectum

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note